Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 281-287

  Bai, Xueli ^a   Zhi, Xiao ^a   Zhang, Qi ^a   Liang, Feng ^a   Chen, Wei ^a   Liang, Chao ^a   Hu, Qida ^a   Sun, Xu ^a   Zhuang, Zhengping ^b   Liang, Tingbo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Angiogenesis; Chemotherapy sensitization; Drug delivery; Vascular permeability; Xenograft model

Indexed keywords

DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LB 100; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ENZYME INHIBITOR; HIF1A PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CAPILLARY PERMEABILITY; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PANCREATIC NEOPLASMS; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEIN PHOSPHATASE 2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908214571     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.048     Document Type: Article

References (33)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30. 10.3322/caac.21166.
2. Wolfgang C.L., Herman J.M., Laheru D.A., Klein A.P., Erdek M.A., Fishman E.K., et al. Recent progress in pancreatic cancer. CA Cancer J. Clin 2013, 63:318-348. 10.3322/caac.21190.
3. Zhuang Z., Lu J., Lonser R., Kovach J.S. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle 2009, 8:3303-3306. 10.4161/cc.8.20.9689.
4. Wei D., Parsels L.A., Karnak D., Davis M.A., Parsels J.D., Marsh A.C., et al. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin. Cancer Res 2013, 19:4422-4432. 10.1158/1078-0432.CCR-13-0788.
5. Bai X.L., Zhang Q., Ye L.Y., Hu Q.D., Fu Q.H., Zhi X., et al. Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol. Cancer Ther 2014, 13:2062-2072. 10.1158/1535-7163.MCT-13-0800.
6. Zhang C., Peng Y., Wang F., Tan X., Liu N., Fan S., et al. A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma. Biomaterials 2010, 31:9535-9543. 10.1016/j.biomaterials.2010.08.059.
7. Martiniova L., Lu J., Chiang J., Bernardo M., Lonser R., Zhuang Z., et al. Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS ONE 2011, 6:e14678. 10.1371/journal.pone.0014678.
8. Zhang Q., Bai X.L., Chen W., Ma T., Hu Q.D., Liang C., et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with HIF-1alpha signaling. Carcinogenesis 2013, 34:962-973. 10.1093/carcin/bgt027.
9. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med 2003, 9:677-684. 10.1038/nm0603-677.
10. Cui J., Mao X., Olman V., Hastings P.J., Xu Y. Hypoxia and miscoupling between reduced energy efficiency and signaling to cell proliferation drive cancer to grow increasingly faster. J. Mol. Cell. Biol 2012, 4:174-176. 10.1093/jmcb/mjs017.
11. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 2011, 364:1817-1825. 10.1056/NEJMoa1011923.
12. Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med 2013, 369:1691-1703. 10.1056/NEJMoa1304369.
13. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461. 10.1126/science.1171362.
14. Chauhan V.P., Martin J.D., Liu H., Lacorre D.A., Jain S.R., Kozin S.V., et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun 2013, 4:2516. 10.1038/ncomms3516.
15. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trials of the cancer and leukemia group B (CALGB 80303). J. Clin. Oncol 2010, 28:3617-3622. 10.1200/JCO.2010.28.1386.
16. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol 2009, 27:2231-2237. 10.1200/JCO.2008.20.0238.
17. Seshacharyulu P., Pandey P., Datta K., Batra S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013, 335:9-18. 10.1016/j.canlet.2013.02.036.
18. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007, 130:21-24. 10.1016/j.cell.2007.06.034.
19. Westermarck J., Hahn W.C. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol. Med 2008, 14:152-160. 10.1016/j.molmed.2008.02.001.
20. Li W., Li D.M., Chen K., Chen Z., Zong Y., Yin H., et al. Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the alpha-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study. BMC Cancer 2012, 12:547. 10.1186/1471-2407-12-547.
21. Li W., Chen Z., Gong F.R., Zong Y., Chen K., Li D.M., et al. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway. Eur. J. Cancer 2011, 47:2654-2664. 10.1016/j.ejca.2011.08.014.
22. Lu J., Kovach J.S., Johnson F., Chiang J., Hodes R., Lonser R., et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:11697-11702. 10.1073/pnas.0905930106.
23. Wei W., Shi Q., Remacle F., Qin L., Shackelford D.B., Shin Y.S., et al. Hypoxia induces a phase transition within a kinase signaling network in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E1352-E1360. 10.1073/pnas.1303060110.
24. Schug M., Stober R., Heise T., Mielke H., Gundert-Remy U., Godoy P., et al. Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen-induced gene expression alterations in rat liver and cultivated hepatocytes. Arch. Toxicol 2013, 87:337-345. 10.1007/s00204-012-0999-8.
25. Zhao Z., Koeplinger K.A., Padbury G.E., Aaron C.S., Harbach P.R., Mayo J.K., et al. Contribution of serum protein association to discrepancy between the in vivo and in vitro UDS results for 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843). Mutat. Res 1997, 395:119-126. 10.1016/S1383-5718(97)00152-6.
26. Lacobelli S., Ranelletti F.O., Longo P., Riccardi R., Mastrangelo R. Discrepancies between in vivo and in vitro effects of glucocorticoids in myelomonocytic leukemic cells with steroid receptors. Cancer Res 1978, 38:4257-4262.
27. Ruediger R., Ruiz J., Walter G. Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol. Cell. Biol 2011, 31:3832-3844. 10.1128/MCB.05744-11.
28. Bartholin L. Pancreatic cancer and the tumor microenvironment: mesenchyme's role in pancreatic carcinogenesis. Pancreatic Cancer and Tumor Microenvironment 2012, Chapter 4, Transworld Research Network, Trivandrum (India). P.J. Grippo, H.G. Munshi (Eds.).
29. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev 2004, 56:549-580. 10.1124/pr.56.4.3.
30. Gavard J., Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol 2006, 8:1223-1234. 10.1038/ncb1486.
31. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol 1996, 16:4604-4613.
32. Ma J., Sawai H., Ochi N., Matsuo Y., Xu D., Yasuda A., et al. PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol. Cell. Biochem 2009, 331:161-171. 10.1007/s11010-009-0154-x.
33. Choi S.B., Park J.B., Song T.J., Choi S.Y. Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line. Int. J. Mol. Med 2011, 28:449-454. 10.3892/ijmm.2011.719.